EUROpean Intracoronary Cooling Evaluation in Patients With ST-elevation Myocardial Infarction. (EURO-ICE)
Status
Conditions
Treatments
Details and patient eligibility
About
In acute myocardial infarction, early restoration of epicardial and myocardial blood flow is of paramount importance to limit infarction size and create optimum conditions for favourable long-term outcome. Currently, restoration of epicardial blood flow is preferably and effectively obtained by primary percutaneous coronary intervention (PPCI). After opening the occluded artery, however, the reperfusion process itself causes damage to the myocardium, the so called "reperfusion injury". The phenomenon of reperfusion injury is incompletely understood and currently there is no established therapy for preventing it. Contributory factors are intramyocardial edema with compression of the microvasculature, oxidative stress, calcium overload, mitochondrial transition pore opening, micro embolization, neutrophil plugging and hyper contracture. This results in myocardial stunning, reperfusion arrhythmias and ongoing myocardial necrosis. There is general agreement that a large part of the cell death caused by myocardial reperfusion injury occurs during the first few minutes of reperfusion, and that early treatment is required to prevent it.
Myocardial hypothermia may attenuate the pathological mechanisms mentioned above. However, limited data are available on the beneficial effects of hypothermia to protect the myocardium from reperfusion damage. In animals, several studies demonstrated a protective effect of hypothermia on the infarction area. This effect was only noted when hypothermia was established before reperfusion. Hypothermia is therefore thought to attenuate several damaging acute reperfusion processes such as oxidative stress, release of cytokines and development of interstitial or cellular edema. Furthermore, it has been shown that induced hypothermia resulted in increased ATP-preservation in the ischemic myocardium compared to normothermia. The intracoronary use of hypothermia by infused cold saline in pigs was demonstrated to be safe by Otake et al. In their study, saline of 4°C was used without complications (such as vasospasm, hemodynamic instability or bradycardia) and it even attenuated ventricular arrhythmia significantly.
Studies in humans, however, have not been able to confirm this effect, which is believed to be mainly due to the fact that the therapeutic temperature could not reached before reperfusion in the majority of patients or not achieved at all. Furthermore, in these studies it was intended to induce total body hypothermia, which in turn may lead to systemic reactions such as shivering and enhanced adrenergic state often requiring sedatives, which may necessitate artificial ventilation.
In fact, up to now any attempt to achieve therapeutic myocardial hypothermia in humans with myocardial infarction, is fundamentally limited because of four reasons:
- Inability to cool the myocardium timely, i.e. before reperfusion
- Inability to cool the diseased myocardium selectively
- Inability to achieve an adequate decrease of temperature quick enough
- Inability to achieve an adequate decrease of temperature large enough
Consequently, every attempt to achieve effective hypothermia in ST-segment myocardial infarction in humans has been severely hampered and was inadequate. In the last two years, the investigators have developed a methodology overcoming all of the limitations mentioned above. At first, the investigators have tested that methodology in isolated beating pig hearts with coronary artery occlusion and next, the investigators have tested the safety and feasibility of this methodology in humans.
Therefore, the time has come to perform a proof-of-principle study in humans, which is the subject of this protocol.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Acute anterior wall ST-elevation myocardial infarction
- Total ST-segment deviation of at least 5 mm
- Presenting within 6 hours after onset of complaints
- TIMI 0 or 1 flow in the LAD
- Hemodynamically stable and in an acceptable clinical condition
- Able to give informed consent
Exclusion criteria
- Age <18 year or >80 year
- Cardiogenic shock or hemodynamically unstable patients
- Patients with previous myocardial infarction in the culprit artery of with previous bypass surgery
- Very tortuous or calcified coronary arteries
- Complex or long-lasting primary PCI expected
- Severe concomitant disease or conditions with a life expectancy of less than one year
- Inability to understand and give informed consent
- Known contra-indication for MRI
- Pregnancy
- Severe conduction disturbances necessitating implantation of temporary pacemaker
Trial design
Primary purpose
Allocation
Interventional model
Masking
200 participants in 2 patient groups
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal